Again, NADH is also known as CoQ1. CoQ10 is a different substance (Equinone
is an alternate name for CoQ10.
NADH/Enada/CoQ1 are claimed to have special qualities for Parkinsons.
Both CoQ1 and CoQ10 are purported to be good energizer
Below are all the references to studies re CoQ1 (NADH) that I could find in
our archives:
------------------------------------------------------------------
Studies -
>>> Posting number 3693, dated 30 Jun 1995 03:47:19
From: Wendy Tebay <[log in to unmask]>
This info is taken from Dr. Atkins "Health Revelations" Newsletter...
>>> Posting number 7656, dated 22 Dec 1995 17:53:21
From: Lisa Carper <[log in to unmask]>
Coenzyme Q10 and nicotinamide and a free radical spin trap protect against
MPTP neurotoxicity.
Schulz JB; Henshaw DR; Matthews RT; Beal MF
Neurochemistry Laboratory, Massachusetts General Hospital, Boston 02114, USA
Exp Neurol (United States) Apr 1995,132 (2) p279-83
1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) produces Parkinsonism in
both experimental animals and in man. MPTP is metabolized to
1-methyl-4-phenylpridinium, an inhibitor of mitochondrial comple I. MPTP
administration produces ATP depletions in vivo, which may lead to secondary
excitotoxicity and free radical generation. If this is the case then agents
which improve mitochondrial function or free radical scavengers should
attenuate MPTP neurotoxicity. In the present experiments three regimens of
MPTP administration produced varying degrees of striatal dopamine depletion.
A combination of coenzyme Q10 and nicotinamide protected against both mild
and moderate depletion of dopamine. In the MPTP regimen which regemin which
produced mild dopamine depletion nicotinamide or the free radical spin trap
N-tert-butyl-alpha-(2-sulfonphenyl)-nitrone were also effective. There was
no protection with a MPTP regimen which produced severe dopamine depletion.
These results show that agents which improve mitochondrial energy production
(coenzyme Q10 and nicotinamide NADH) and free radical scavengers can
attenuate mild to moderate MPTP neurotoxicity.
--
>>> Posting number 14913, dated 7 Oct 1996 21:52:26
From: "Paul S. McCahan" <[log in to unmask]>
Subject: NADH, nicotinamide adenine dinucleotide??
I think he said work was done on it in Austria by a Mr./Dr. Vrecko; he said
that there >was a paper published in 1993.
>>> Posting number 19180, dated 22 Jan 1997 12:38:38
From: Ivan M Suzman <[log in to unmask]>
I spoke to Dr.Georg Birkmayer of Vienna, the developer of ENADA-brand NADH,
this morning. He also mentioned the research work at the Univ. of Paris on
another study NADH users.
>>> Posting number 19851, dated 5 Feb 1997 03:24:33
From: Bob & Joy Graham <[log in to unmask]>
I found this abstract from the Fourth International Congress of Movement
Disorders, Vienna, June 1996. It can be located in the journal "Movement
Disorders", Vol. 11, Supplement 1, 1996 (paper 725, p. 194). What follows
is my slight reduction of the abstract, without some of the stats.
Clinical Improvement of Parkinsonian symptoms after parenteral application
of NADH.
W Kuhn et al, Department of Neurology, St Josef Hospital, Ruhr-University
of Bochum Gudrunstr. 56, 44791 Bochum (?)
Introduction:
Reduced coenzyme nicotinamide adenine dinucleotide (NADH) may stimulate
endogenous biosynthesis of L-Dopa (Vrecko, K et al. J Neural Transm Park
Dis Dement Sect 1993; 5 (2): 147-156) and therefore may represent a new
therapeutic approach to PD (Birkmayer, JG et al Acta Neurol Scand Suppl
1993; 146: 32-35).
Material and Methods: To test the clinical potential of a newly developed
pharmaceutical preparation (Mattern & Partner, Germany), NADH was
intravenously applied over a period of 7 days (10mg/500ml 0.9% NaCl per
day, infusion time 8am to 9am) in 14 patients...in advanced stages ...of
PD. Mean duration of PD was 7.5 to 9.0 years. The clinical symptoms were
scored by using the Unified PD Ratings Scale (UPDRS). The mean UPDRS score
at day 0... was significantly higher [I guess this means worse] than after
application of i.v.NADH over 7 days.
Conclusion: Parenteral application of NADH may be of therapeutic value in
PD and should further be investigated in double-blind, placebo-controlled
trials.
>>> Posting number 26131, dated 19 Jun 1997 02:07:16
From: Forrests Mom <[log in to unmask]>
References:
1. Lehninger, A.L. (1970): Biochemistry, Worth Publisher Inc. 1970.
2. Klingenberg M. (1960): Zur Bedeutung der freien Nucleotide. 11.Moosbacher
Kolloquium Springer Verlag p. 82-114
3. Sauberlich H.E. (1987): Nutritional Aspects of Pyridine Nucleotides, in
Dolphin D, Poulson R., Avramovic O. (editors): Pyridine Nucleotide Coenzymes
(Part B), John Wiley & Sons, Inc. 1987, p. 599-626
4. Alberts B, et al (1983): Molecular Biology of the Cell, Garland
Publishing, 1983, p. 491-495.
5. Vrecko K., Birkmayer JGD and Krainz J. (1993): Stimulation of dopamine
biosynthesis in cultured PC12 phaeochromocytoma cells by the coenzyme
nicotinamide adenine dinucleotide (NADH), J. Neur. Trans. 5:147-156
6. Gardier M. (1994) Study Report to Labor Birkmayer, Department
Pharmacology, University Paris Sud.
7. Kaplan N.O. (1960) in Boyer PD, Lardy H. and Myrbaeck K.: The Enzymes
Vol. 3, Ac Press New York p. 156-172
>>> Posting number 69285, dated 6 Oct 1999 10:38:02
From: Susan Trout <[log in to unmask]>
In March 1996 Georgetown University was beginning a study on NADA for
chronic fatigue syndrome; I've not heard of any results. I assume these to
be double blind studies.
Another institute was going to do double blind studies on NADA and
athletes/triathletes performance.
Please let us know what your results are.
>>> Posting number 72547, dated 25 Nov 1999 10:53:07
From: "Kathrynne Holden, MS, RD"
<[log in to unmask]>
NPF is studying Co-Q10 -- check their website at:
http://www.parkinson.org/clnindex.htm
>>> Posting number 75489, dated 30 Jan 2000 03:33:06
From: Audrey <[log in to unmask]>
http://www.centerwatch.com/studies/cat117.htm
http://www.parkinson.org/q10study.htm
Fran Peck wrote:
> Thanks for the responses. I did a PubMed search and found a bazillion
> different pubs on NADH (haven't run a search on Co Q10 yet), but nothing
> that looks like anyone is clinical trialing it for Parkinsons either.
>
> > COenzyme CQ 10 has been commented on (as opposed to " prescribed"
> > which are two different things!) by several if the neuros who
> > have been guest speaker at assorted PD discussions, support
> > groups, and the like which I've attended over the years.
> > Generally, this is in response to specific questions by members in
> > the audience as.
> >
> > MOST of the neuros kind of shrugged and mumbled something like
> > "well this isn't considered to be LEGITIMATE medicine ..." and the
> > next thing ya know, the neuro changes the subject!
> >
> > In the past coupla years, a few neuros have, if not espoused CQ10,
> > have claimed that while it's still considered "alternative
> > medicine" there MIGHT be some value for the PWP in it.
> >
> Fran Peck
> Email: [log in to unmask]
>
> _______________________________________________________
> Say Bye to Slow Internet!
> http://www.home.com/xinbox/signup.html
--
Frans van Duinen
(416) 652-8580
Toronto, Ontario
